Monoclonal Antibody for Delineating CD8+ T Cell Population Subsets (C1.7)
Giorgio Trinchieri and Nicholas Valiante
C1.7 binds to a unique surface marker expressed by a functionally distinct subset of CD8+ T cells. C1.7 can potentially provide a more accurate means of establishing and correlating CD8+ T cell subset predominance in certain diseases. The antibody could significantly advance studies to define the phenotypes, cytotoxic activity and cytokine profiles of CD8+ T cell subset populations.
This technology is protected by U.S. Patent No. 5,688,690.